<DOC>
	<DOCNO>NCT00796601</DOCNO>
	<brief_summary>The hypothesis Study A6061054 demonstrate superiority efficacy esreboxetine 3 6 month compare placebo .</brief_summary>
	<brief_title>Maintenance Efficacy .</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Subjects must meet American College Rheumatology ( ACR ) criteria fibromyalgia Pain score great equal 4 11point NRS FIQTotal score great equal 45 point Other severe pain may confound assessment self evaluation pain associate fibromyalgia Any autoimmune rheumatic disorder , nonfocal rheumatic disease ( fibromyalgia ) , clinically significant active infection , untreated endocrine disorder Uncontrolled hypertension Pending Worker 's Compensation ; Current recent diagnosis episode major depressive disorder , dysthymia and/or uncontrolled depression ; Subjects risk suicide ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>double-blind placebo-controlled maintenance efficacy</keyword>
</DOC>